Amylyx Pharmaceuticals, Inc. Total Liabilities and Equity
Amylyx Pharmaceuticals, Inc. (AMLX) had Total Liabilities and Equity of $264.56 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $264.56M.
- 2026-03-31: Liabilities and Equity $293.60M.
- 2025-12-31: Liabilities and Equity $332.64M.
- 2025-09-30: Liabilities and Equity $362.74M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $264.56M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $293.60M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $332.64M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $362.74M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $194.60M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $219.68M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $193.63M 10-K · filed 2026-03-03 |
| 2024-09-30 | $250.71M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $332.16M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $417.46M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $517.45M 10-K · filed 2025-03-04 |
| 2023-09-30 | $466.58M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $453.59M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $407.96M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $391.45M 10-K · filed 2024-02-22 |
| 2022-09-30 | $181.44M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $225.24M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $274.44M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $105.61M 10-K · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |